Ligand, QLT PhotoTherapeutics Inc. sales and marketing update

LGND's Ligand Pharmaceuticals Inc. Canadian subsidiary began selling QLTIF's light activated Photofrin drug to treat esophageal cancer and superficial bladder cancer. A 75 mg vial costs C$2,650. LGND estimated the per patient cost for the one-time treatment of superficial bladder cancer and esophageal cancer at C$7,000 and C$5,000, respectively. ...